During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for ...

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Lenalidomide offers an exciting advance in the treatment of the 5q– MDS patient. It has the ability to alter the course of MDS by inducing hematologic and cytogenetic responses, resulting in ...

Contacts IR Contacts United States Ran Meir (267) 468-4475 Israel Yael Ashman 972 (3) 914-8262 PR Contacts United States Kelley Dougherty (973) 658-0237 Yonatan Beker (973) 264 7378 ...

Lenalidomide, an immunomodulatory agent with antiangiogenic and antineoplastic properties, is a standard treatment for initial and relapsed multiple myeloma.

Data comparing long-term outcomes in lenalidomide-treated and untreated patients with myelodysplastic syndromes (MDS) with del (5q) are limited. We evaluated clinical outcomes of 295 lenalidomide ...

The primary purpose is to evaluate the safety of lenalidomide in a non-interventional setting. The study began on March 31, 2017, with an estimated completion timeline extending to eight years.

1 Belada D, M.D., Ph.D., et al. A Phase 1b, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in ...

Lenalidomide was combined with pulsed dexamethasone (40 mg/day, days 1–4 and 15–18) after two cycles in five patients, and from the start in three patients (Table 1, patient nos. 9–16).